A Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects

Anesthesia Clinical Trial

Official title:

A Randomized, Positive and Placebo-Controlled Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06379867
• Other study ID #: HSK3486-112
• Status: Recruiting
• Phase: Phase 1
• Start date: April 7, 2024
• Est. completion date: August 30, 2024

Study information

• Verified date: April 2024
• Source: Haisco Pharmaceutical Group Co., Ltd.
• Contact: Chen Meixia
• Phone: 67258779
• Email: chenmeixia[@]haisco.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Assess the effects of a single IV bolus of HSK3486 single dose on cardiac repolarization for healthy subjects.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: August 30, 2024
• Est. primary completion date: May 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Ability to understand and comply with protocol requirements and is willing voluntarily sign written ICF.

2. Healthy participants at age from 18 to 45 years old (inclusive) at Screening.

3. Male body weight =50 kg, female body weight =45 kg, with a body mass index BMI of 19~28 kg/m2 (inclusive).

4. Left Ventricular Ejection Fraction (LVEF)=50%.

Exclusion Criteria:

1. Past or present clinically significant systemic disease as judged by the Investigator including, but not limited to psychiatric, neurologic, pulmonary, respiratory, cardiac, gastrointestinal, genitourinary, renal, hepatic, metabolic, endocrinologic, hematological, or autoimmune disorders.

2. History of allergy to egg or egg products, soybean or soy products.

3. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance. History of allergy to HSK3486 or moxifloxacin or its investigational product excipients, or history of specific allergies (asthma, urticaria, eczema, etc.), or history of tendinitis or tendon rupture due to moxifloxacin or any other quinolone drug.

4. Clinically significant infection/injury/disease within 1 month prior to dosing.

5. Current or recent (< 6 months from screening) hepatobiliary disease.

6. Current or past history of seizure disorder, including alcohol- or stimulant-related seizure, febrile seizure, or significant family history of idiopathic seizure disorder.

7. Family history of sudden death at <50 years of age.

8. History of unexplained loss of consciousness, unexplained syncope, unexplained irregular heartbeats or palpitations, clinically significant head injury.

9. Pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, or conditions that could interfere with the absorption, metabolism, and/or excretion of study drug (e.g., history of bariatric surgery or intestinal bypass surgery; simple uncomplicated appendectomies and hernia repairs are allowed, but cholecystectomy is not allowed).

10. Positive test results for hepatitis B surface antigen, hepatitis C antibody, treponema pallidum antibody, human immunodeficiency virus (HIV) antigen/antibody combination test.

11. Subjects with previous or suspected difficult airway (e.g., modified Mallampti score III-IV, congenital microglossia, mandibular dysplasia), or respiratory insufficiency, history of obstructive pulmonary disease, history of asthma, sleep apnea syndrome; history of failed tracheal intubation; history of bronchospasm requiring treatment within 3 months prior to screening; acute respiratory infection, and with obvious symptoms such as fever, wheezing, nasal congestion or cough within 1 week prior to baseline.

12. Knowledge of any kind of cardiovascular disorder/condition/procedure known to increase the possibility of QT prolongation or history of risk factors for TdP (e.g., heart failure, hypokalemia, hypomagnesemia, congenital Long QT syndrome, or family history of Long QT Syndrome.

13. Laboratory tests at screening or baseline judged clinically significant by the investigator, including, but not limited to, ALT or AST > 1.2 ×ULN (the upper limit of the reference range at screening or baseline), direct bilirubin > ULN (congenital nonhemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's syndrome based on total and direct bilirubin] is not acceptable), creatine kinase (CK) > ULN (one repeat test allowed), thyroid stimulating hormone (TSH) outside normal range (0.75 to 5.6 mIU/L) , serum potassium outside normal range (3.5 to 5.3 mmol/L).

14. Rest sitting vital sign results abnormal and clinically significant at screening or baseline, ear temperature outside normal range, diastolic blood pressure = 90 mmHg or systolic blood pressure = 140 mmHg, HR < 55 beats/min or > 100 beats/min (test can be repeated once according to investigator's judgment).

15. Oxygen saturation (SpO2) below 95% at baseline.

16. Abnormal 12-lead ECG at screening or baseline (any test abnormality), including any of

the following:

1. QTcF > 450 ms

2. QRS > 110 ms

3. PR > 200 ms

4. Second or third-degree AV block

5. Any rhythm other than sinus rhythm of clinical significance.

17. Estimated Glomerular Filtration Rate (eGFR) < 90 mL/min (estimated using MDRD equation).

18. Participation in another clinical study of an investigational drug (or medical device) within 3 months (or 5 half-lives, whichever is longer) prior to dosing, or previous participation in any other clinical trial related to HSK3486.

19. Donation of blood within 3 months prior to screening, plasma within 2 weeks prior to screening, platelets within 6 weeks prior to screening, or receive blood products within 2 months prior to admission to a the investigational site.

20. Sperm and egg donation program from screening period to 90 days after study end.

21. Pregnant or lactating women or those with positive pregnancy test results. Male or female subjects of childbearing potential do not agree to use an effective method of contraception from the time of signing ICF until 90 days after leaving the investigational site after the last dose (see Appendix 6 for details of specific contraceptive methods).

22. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing or during the clinical trial.

23. Use or intend to use of any prescription, nonprescription, vitamin, herbal, or nutraceutical within 14 days prior to dosing or during the clinical trial.

24. Smoking (= 5 cigarettes per day) within 6 months prior to screening, or inability to quit smoking during the trial.

25. Positive alcohol breath test, or regular drinking within 6 months prior to dosing or during the trial, i.e. drinking more than 21 units (men) or 14 units (women) of alcohol per week (1 unit =360 mL beer or 45 mL spirits or 150 mL wine at 40% alcohol).

26. Positive urine drug abuse screening (morphine, tetrahydrocannabinol, methamphetamine, methylenedioxyamphetamine, ketamine), or history of drug abuse, drug dependence within 6 months prior to screening, or drug use within 3 months prior to screening.

27. Subjects who tested positive for COVID-19 during screening.

28. Eating fruits or foods affecting metabolic enzymes, such as grapefruit (citrus), pomelo, etc., within 7 days prior to screening; and not abstaining from the above beverages, fruits or foods during the study period.

29. Previous chronic excessive consumption (more than 8 cups per day, 1 cup =250 mL) of tea, coffee or caffeinated beverages, or intake of caffeine and/or purine-rich foods or beverages (e.g. coffee, tea, chocolate, caffeinated carbonated beverages, cola, etc.) within 48 hours prior to screening, or refusal to stop drinking tea, coffee and/or caffeinated beverages during the trial.

30. Performing or unwilling to refrain from strenuous physical activity, which could cause muscle aches or injury, including contact sports, at any time from 3 days prior to dosing through the end-of-study visit.

31. Subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical disease (e.g., infectious disease).

32. Any condition or situation that, in the opinion of the investigator, would prevent proper evaluation of the safety or efficacy of the study drug according to the study protocol (e.g., poorly compliant subject, poorly vascular condition, allergies to medical plastics/latex).

Related Conditions & MeSH terms

• Anesthesia

Intervention

Drug:
• HSK3486
0.4 mg/kg, IV bolus administration
• Placebo
IV bolus administration
• Moxifloxacin
0.4 g, Oral administration with 240 mL

Locations

Country	Name	City	State
China	Beijing GoBroad Boren Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Haisco Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	?QTcI	The change-from-baseline in QTc interval, corrected for HR using the individual QT correction method (QTcI).	Pre-dose and at multiple timepoints post-dose on Days 1 to 2 in each period.
Secondary	?HR, ?QTcF, ?PR, and ?QRS	Change-from-baseline HR, QTcF, PR, and QRS intervals, which will be used as the dependent variable for calculation of model-derived ??HR, ??QTcF, ??PR, and ??QRS for the by-time point analysis, respectively.	Pre-dose and at multiple timepoints post-dose on Days 1 to 2 in each period.
Secondary	Categorical outliers for QTcI, QTcF, HR, PR, and QRS intervals	Categorical outliers for QTcI, QTcF, HR, PR, and QRS intervals.	Pre-dose and at multiple timepoints post-dose on Days 1 to 2 in each period.
Secondary	AE and SAE	Incidence of AE and SAE	Up to Day 18
Secondary	Cmax	Maximum Observed Plasma Concentration	Pre-dose and at multiple timepoints post-dose on Days 1 to 2 in each period
Secondary	AUClast	Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration of HSK3486	Pre-dose and at multiple timepoints post-dose on Days 1 to 2 in each period
Secondary	t1/2	Elimination Half-Life	Pre-dose and at multiple timepoints post-dose on Days 1 to 2 in each period